Save the date for the 9th Annual BioHealth Capital Region Forum on September 19th and 20th, 2023! Join us for two days of highlighting innovation and entrepreneurship as we bring together the best of our region and beyond to collaborate and shape the future of healthcare. Location and registration information coming soon.

The deal stands to drive hundreds of millions more to the local company over time.

Image: Scott Koenig is president and CEO of Rockville's MacroGenics. JOANNE S. LAWTON

Join us and guest speaker John Newby, CEO of Virginia Bio, who will be highlighting strategic goals for Virginia Bio and Virginia Bio-Connect as well as discussing the future of biotech collaborations and partnerships in the DMV region. Enjoy an evening of networking, drinks, and fun!

Want to be on the cutting edge of disease treatment? Learn how companies like Immunyx Pharma are changing the landscape of immune modulation in the battle against diseases with the JLABS/BARDA Blue Knight program on this episode of BioTalk with Rich Bendis.

Also Available on popular podcast platforms like Apple https://apple.co/3LlbxIy, Google https://bit.ly/3l6O6ba, Spotify https://spoti.fi/405ln5B, Amazon Music https://amzn.to/3J58kde, TuneIn https://bit.ly/3JA8MBO, and even YouTube https://bit.ly/3LhYZS6.

LEIDEN, the Netherlands, March 07 / B3C newswire / -- MIMETAS, a leading company in the field of organ-on-a-chip-based disease models, announces that it has launched its Adult Stem Cell (ASC)-derived tubular organoids in an assay-ready format. As part of its OrganoReady® product line, MIMETAS offers two organoid-based products: ASC-derived Colon1 and Kidney2 Organoid tubules.

“We are thrilled to offer this cutting-edge technology to the research community,” says Jos Joore, co-CEO of MIMETAS. “We’ve worked for several years to optimize these OrganoReady® organoid products. As a result, our early-access users will be the first in the world to have license-free access to ready-to-use, donor-relevant organoid tubules of consistent quality.”

In the field of artificial intelligence, there are winters and there are springs—barren stretches followed by exhilarating bursts of innovation and funding. Right now, we find ourselves definitively in the midst of an AI spring, says Johns Hopkins engineer Rama Chellappa, a veteran of the industry for more than four decades.

ROCKVILLE, MARYLAND, March 8, 2023 – BioHealth Innovation Inc. (BHI) is pleased to welcome Mona Suliman, Ph.D., as a new Life Sciences Business Strategist. In this role, Mona will evaluate the commercial potential of clients’ emerging technologies and assist start-ups with their go-to-market strategies. Her work will also focus on helping biohealth companies to secure non-dilutive funding.

Mona Suliman has been a consultant in the business and science sectors for over eight years. Her specific areas of focus are entrepreneurship, innovation, strategy, and marketing. She obtained her Master’s in Business Administration from George Mason University and her Ph.D. in Biochemistry from Virginia Commonwealth University in Richmond. As a consultant, she supported companies in developing marketing strategies and creating product launch plans and development strategies.

“We are thrilled to welcome Mona to BHI,” said Richard Bendis, BHI President, and CEO. “I am confident Mona will bring a unique perspective and energy to our team and BioHealth Partners.”

About BioHealth Innovation, Inc. 

BioHealth Innovation, Inc. (BHI) is a public-private nonprofit organization focused on accelerating biohealth (therapeutic, diagnostic, medtech, and health IT) commercialization in the BioHealth Capital Region (Maryland, DC, and Virginia).

www.BioHealthInnovation.org

# # #

Media contacts:
Rich Bendis
Phone: 301-637-6439, email: This email address is being protected from spambots. You need JavaScript enabled to view it.

Lucy Alexander, Capabilities Lead, Global Supply Chain & Strategy with AstraZeneca, joins Rich Bendis on BioTalk to discuss leading world-class supply chain operations, developing new strategies, and the continued growth of AZ in the BioHealth Capital Region.

Listen via Apple https://apple.co/3Zov7b7, Google https://bit.ly/3JfYiav, Spotify https://spoti.fi/3ZGPekn, Amazon Music https://amzn.to/3ZqknsP, and TuneIn http://bit.ly/2M60Wmx.

The BioHealth Innovation, Inc. (BHI) team would like to extend its deepest gratitude to Sarah Miller, Vice President of Economic Development, for her invaluable contributions to the organization as she moves on to a new opportunity. Sarah has played an integral role in BHI's mission to accelerate the commercialization of BioHealth technologies and worked tirelessly to build and maintain strong relationships with industry stakeholders and partners. Her dedication and hard work will be greatly missed, and we wish her all the best in her future endeavors.

The Shady Grove Innovation District is a planned mixed-use, transit-served innovation ecosystem of more than 1.3M SF located in Maryland’s premier life sciences cluster.

BXP, formerly Boston Properties, recently unveiled plans at its pre-application community meeting to develop the Shady Grove Innovation District (“SGID”), a world-class, amenity-rich, mixed-use district catering to the dynamic life science industry in the heart of the Shady Grove cluster in Rockville, Maryland.  SGID will initially include 150,000 square feet of lab/R&D space in a five-story building and 315 luxury apartments. The district has the potential to grow to more than 1.3M square feet of lab/R&D space across a total of nine buildings.  Construction could begin as early as mid-2024.